Total: $16.61M

Year to Date: $39.28M

Company (Symbol)#*

Partner (Country)

Amt.(M)

Details (Date)


Ansaris Inc. (Blue Bell, Pa.)

Ono Pharmaceutical Co. Ltd. (Osaka, Japan)

ND

For the successful identification of a kinase-related compound under its drug discovery collaboration (2/9)

Astex Therapeutics (Cambridge, UK)

Wellcome Trust

£1 ($1.61)

To support the company's work in the area of infectious disease caused by hepatitis C virus (2/2)

Cellzome (Heidelberg, Germany)

GlaxoSmithKline plc (London)

ND

As part of their epigenetics alliance (2/9)

Halozyme Therapeutics Inc. (San Diego)

Roche AG (Basel, Switzerland)

$5

For the start of a Phase III trial of MabThera using Enhanze technology (2/17)

MorphoSys AG (Martinsried, Germany)

Novartis AG (Basel, Switzerland)

ND

For completing the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research (2/23)

Perseid Therapeutics LLC (unit of Maxygen Inc.; Redwood City, Calif.)

Astellas Pharma Inc. (Tokyo)

$10

For the start of a Phase I study to evaluate a CTLA4-Ig therapeutic to treat rheumatoid arthritis and other autoimmune indications (2/1)

Phylogica Ltd. (Perth, Australia)

Roche AG (Basel, Switzerland)

ND

For the completion of the first stage of the collaboration that used Phylogica's Phylomer drug discovery platform to identify novel cell-penetrating peptides for targeting intracellular disease pathways (2/18)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; * Private company. Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed. ** Denotes the date the item ran in BioWorld International.